| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
RESEARCH COMMUNICATION |
a Department of Oncology Drug Discovery, Bristol-Myers Squibb Pharmaceuticals, Inc., Princeton, New Jersey 08543, USA
b Department of Chemistry, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213–2683, USA
c Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, USA
d Department of Chemistry and Biochemistry, University of Bern, CH-3012 Bern, Switzerland
Angiogenesis is a complex process that involves endothelial cell proliferation, migration, basement membrane degradation, and neovessel organization. Angiostatin, consisting of four homologous triple-disulfide bridged kringle domains, has previously been shown to exhibit profound inhibition of endothelial cell proliferation in vitro and angiogenesis in vivo. It was also demonstrated that angiostatin could suppress the growth of a variety of tumors via the blocking of angiogenesis. The primary aim of our study was to characterize the kringle domains of angiostatin for their inhibitory activities of endothelial cell migration in order to elucidate their contributions to the anti-angiogenic function of angiostatin. In this report, we demonstrate for the first time that the kringles of angiostatin play different roles in inhibiting endothelial cell migration, a crucial process in angiogenesis. Kringle 4, which has only marginal anti-proliferative activity, is among the most potent fragments in inhibiting endothelial cell migration (IC50 of approximately 500 nM). In contrast, kringle 1–3, which is equivalent to angiostatin in inhibiting endothelial cell proliferation, manifests only a modest anti-migratory effect. The combination of kringle 1–3 and kringle 4 results in an anti-migratory activity comparable to that of angiostatin. When kringle 1 is removed from kringle 1–3, the resulting kringle 2–3 becomes more potent than kringle 1–3. This implies that kringle 1, although virtually ineffective in inhibiting endothelial cell migration, may influence the conformation of kringle 1–3 to alter its anti-migratory activity. We also show that disruption of the kringle structure by reducing/alkylating agents markedly attenuates the anti-migratory activity of angiostatin, demonstrating the significance of kringle conformation in maintaining the anti-angiogenic activity of angiostatin. Our data suggest that different kringle domains may contribute to the overall anti-angiogenic function of angiostatin by their distinct anti-migratory activities.—Ji, W. R., Castellino, F. J., Chang, Y., DeFord, M. E., Gray, H., Villarreal, X., Kondri, M. E., Marti, D. N., Llinás, M., Schaller, J., Kramer, R. A., and Trail, P. A. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J. 12, 1731–1738 (1998)
Key Words: plasminogen • kringle, • BCE cells • fibroblast growth factor
This article has been cited by other articles:
|
|
 |
|
  T. M. B. Nguyen, I. V. Subramanian, A. Kelekar, and S. Ramakrishnan Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells Blood, June 1, 2007; 109(11): 4793 - 4802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, J. A. Doll, K. Jiang, D. L. Cundiff, J. S. Czarnecki, M. Wilson, K. M. Ridge, and G. A. Soff Differential Binding of Plasminogen, Plasmin, and Angiostatin4.5 to Cell Surface {beta}-Actin: Implications for Cancer-Mediated Angiogenesis. Cancer Res., July 15, 2006; 66(14): 7211 - 7215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schmidt, J. Hoffend, A. Altmann, L. G. Strauss, A. Dimitrakopoulou-Strauss, B. Engelhardt, D. Koczan, J. Peter, T. J. Dengler, W. Mier, et al. Angiostatin Overexpression in Morris Hepatoma Results in Decreased Tumor Growth but Increased Perfusion and Vascularization J. Nucl. Med., March 1, 2006; 47(3): 543 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bratt, O. Birot, I. Sinha, N. Veitonmaki, K. Aase, M. Ernkvist, and L. Holmgren Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility J. Biol. Chem., October 14, 2005; 280(41): 34859 - 34869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nyberg, L. Xie, and R. Kalluri Endogenous Inhibitors of Angiogenesis Cancer Res., May 15, 2005; 65(10): 3967 - 3979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Carroll, L. L. Nikitenko, R. Bicknell, and A. L. Harris Antiangiogenic Activity of a Domain Deletion Mutant of Tissue Plasminogen Activator Containing Kringle 2 Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chavakis, A. Athanasopoulos, J.-S. Rhee, V. Orlova, T. Schmidt-Woll, A. Bierhaus, A. E. May, I. Celik, P. P. Nawroth, and K. T. Preissner Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment Blood, February 1, 2005; 105(3): 1036 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Burwick, M. L. Wahl, J. Fang, Z. Zhong, T. L. Moser, B. Li, R. A. Capaldi, D. J. Kenan, and S. V. Pizzo An Inhibitor of the F1 Subunit of ATP Synthase (IF1) Modulates the Activity of Angiostatin on the Endothelial Cell Surface J. Biol. Chem., January 21, 2005; 280(3): 1740 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Majumdar, T. Tarui, B. Shi, N. Akakura, W. Ruf, and Y. Takada Plasmin-induced Migration Requires Signaling through Protease-activated Receptor 1 and Integrin {alpha}9{beta}1 J. Biol. Chem., September 3, 2004; 279(36): 37528 - 37534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Perchick and H. N. Jabbour Cyclooxygenase-2 Overexpression Inhibits Cathepsin D-Mediated Cleavage of Plasminogen to the Potent Antiangiogenic Factor Angiostatin Endocrinology, December 1, 2003; 144(12): 5322 - 5328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Daly, A. Makris, M. Reed, and C. E. Lewis Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment? J Natl Cancer Inst, November 19, 2003; 95(22): 1660 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Arakaki, T. Nagao, R. Niki, A. Toyofuku, H. Tanaka, Y. Kuramoto, Y. Emoto, H. Shibata, K. Magota, and T. Higuti Possible Role of Cell Surface H+-ATP Synthase in the Extracellular ATP Synthesis and Proliferation of Human Umbilical Vein Endothelial Cells Mol. Cancer Res., November 1, 2003; 1(13): 931 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Levchenko, K. Aase, B. Troyanovsky, A. Bratt, and L. Holmgren Loss of responsiveness to chemotactic factors by deletion of the C-terminal protein interaction site of angiomotin J. Cell Sci., September 15, 2003; 116(18): 3803 - 3810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Hanford, C. A. Wong, H. Kassan, D. L. Cundiff, N. Chandel, S. Underwood, C. A. Mitchell, and G. A. Soff Angiostatin4.5-mediated Apoptosis of Vascular Endothelial Cells Cancer Res., July 15, 2003; 63(14): 4275 - 4280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Kim, Y.-K. Hong, Y. A. Joe, Y. Lee, J.-Y. Shin, H.-E. Park, I.-H. Lee, S.-Y. Lee, D.-K. Kang, S.-I. Chang, et al. Anti-angiogenic Activity of the Recombinant Kringle Domain of Urokinase and Its Specific Entry into Endothelial Cells J. Biol. Chem., March 21, 2003; 278(13): 11449 - 11456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tarui, M. Majumdar, L. A. Miles, W. Ruf, and Y. Takada Plasmin-induced Migration of Endothelial Cells. A POTENTIAL TARGET FOR THE ANTI-ANGIOGENIC ACTION OF ANGIOSTATIN J. Biol. Chem., September 6, 2002; 277(37): 33564 - 33570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tarui, L. A. Miles, and Y. Takada Specific Interaction of Angiostatin with Integrin alpha vbeta 3 in Endothelial Cells J. Biol. Chem., October 19, 2001; 276(43): 39562 - 39568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Troyanovsky, T. Levchenko, G. Mansson, O. Matvijenko, and L. Holmgren Angiomotin: An Angiostatin Binding Protein That Regulates Endothelial Cell Migration and Tube Formation J. Cell Biol., March 19, 2001; 152(6): 1247 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ambs, S. Dennis, J. Fairman, M. Wright, and J. Papkoff Inhibition of Tumor Growth Correlates with the Expression Level of a Human Angiostatin Transgene in Transfected B16F10 Melanoma Cells Cancer Res., November 1, 1999; 59(22): 5773 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Goretzki, C. R. Lombardo, and W. B. Stallcup Binding of the NG2 Proteoglycan to Kringle Domains Modulates the Functional Properties of Angiostatin and Plasmin(ogen) J. Biol. Chem., September 8, 2000; 275(37): 28625 - 28633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Graversen, C. Jacobsen, B. W. Sigurskjold, R. H. Lorentsen, S. K. Moestrup, H. C. Thogersen, and M. Etzerodt Mutational Analysis of Affinity and Selectivity of Kringle-Tetranectin Interaction. GRAFTING NOVEL KRINGLE AFFINITY ONTO THE TETRANECTIN LECTIN SCAFFOLD J. Biol. Chem., November 22, 2000; 275(48): 37390 - 37396. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
